Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will cover key topics of interest to stakeholders who set practice policy and will be called upon to evaluate and make decisions on issues pertaining to biosimilars.
Choose from the criteria below to find an activity that fits you best.
NOTE: If you attended the live CE activity titled "Improving Medication Safety in the Radiology Setting" that was held on December 8, 2014 during the 49th ASHP Midyear Clinical Meeting & Exhibition in Anaheim, California AND received CE credit (i.e. a pharmacist CE statement with ACPE Universal Activity Number 0221-9999-14-227-L05-P), you are NOT allowed to also receive CE credit for this home-study activity.
Radiology departments often use medications in ways that are different from other clinical areas of the hospital, and staff may not be aware of the significant safety issues that can arise. This webinar will explore current medication safety issues in the radiology setting, such the safe use of contrast, appropriate labeling of containers, beyond-use dating, and patient identification. Nationally known experts will discuss actual cases in which errors have occurred, and will describe risk-reduction strategies, including use of technology and best practices. Faculty will also discuss an Imaging Bulk Package for contrast recently approved by the US Food and Drug Administration, as well as regulatory and Joint Commission accreditation requirements for use of contrast and other medications in radiology.
The target audience for this activity includes pharmacists and radiologic technologists. Upon completion of this activity, participants will be able to:
Janice Dunsavage, RPh, MAS
Director of Pharmacy
Matthew P. Fricker, Jr., MS, RPh, FASHP
Institute for Safe Medication Practices
Lior Molvin, (MBA) (RT) (R) (CT)
CT Protocol Technologist
CT Protocol Development and Education Team
Stanford University Medical Center and Stanford Medicine, Imaging Center
Palo Alto, California
Darryl S. Rich, PharmD, MBA, FASHP
Medication Safety Specialist
Institute for Safe Medication Practices
It is the policy of ISMP and ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. Today’s speakers have no relevant commercial and/or financial relationships to disclose.
Please note: The opinions expressed in this activity should not be construed as those of the CME/CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include unlabeled indications. Use of drugs and devices outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.
Release Date: 06-15-2015
Expiration Date: 06-15-2018
This CE activity is jointly provided by ProCE, Inc. and the Institute for Safe Medication Practices (ISMP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-15-089-H05-P has been assigned to this knowledge-based, home-study activity. This CE activity is approved for 2.0 contact hours (0.20 CEU) in states that recognize ACPE providers, and is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. CE credit will be uploaded to NABP/CPE Monitor. No partial credit will be given.
Approved by the ASRT for Category A continuing education credit.
This activity is supported by an educational grant from Bracco Diagnostics.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.